Glaukos announced that an analysis published in the Journal of Medical Economics evaluating various options for treating elevated IOP in open-angle glaucoma patients showed that two iStent Trabecular Micro-Bypass Stents had a lower projected average cumulative cost at 5 years than either selective laser trabeculoplasty (SLT) or topical glaucoma medication only.
The population-based, annual state-transition, probabilistic, cost-of-care model used in the analysis was designed to assess direct costs for three treatment options – two iStents, SLT or topical medication only – over a 5-year time horizon. A clinician panel provided treatment strategy change probabilities and direct costs for drugs, procedures and complications that were included in the analysis.
According to the study authors, the projected average cumulative cost at 5 years was $4,420 for the two-stent procedure, compared to $4,730 for SLT and $6,217 for topical medication only. The model showed that while the two-stent procedure had the highest initial year cost, it also had the lowest annual marginal cost for each subsequent year. Over the same time period, costs in each year following SLT or topical medication only were more than double that of the two-stent procedure, according to a Glaukos news release.
“While numerous international studies have shown the ability of two trabecular meshwork stents to effectively control IOP in open-angle glaucoma patients, this analysis is the first to reveal the potential cost efficiency of trabecular stenting, especially over longer time horizons,” John P. Berdahl, MD, a South Dakota-based ophthalmic surgeon and one of the authors of the Journal of Medical Economics article, said in the news release. “Our research indicates that the two-stent treatment option may reduce glaucoma-related health resource use and contribute to direct cost savings, particularly when compared to topical medication only, which is the most commonly used treatment option today but is often ineffective due to high rates of patient non-compliance.”.
The company also is pursuing FDA approval of two versions of its next-generation iStent inject Trabecular Micro-Bypass device: one for use in combination with cataract surgery and another for use in a standalone procedure. The iStent inject is designed to deploy two stents into separate trabecular meshwork locations and is being evaluated in FDA clinical trials for IOP reduction. The iStent inject is approved for use in the European Union, Canada, Australia, Singapore and Brazil. The company also is pursuing FDA approval of a third MIGS device, the iStent SUPRA, which accesses the uveoscleral pathway for aqueous humor outflow.
“Our core strategy is to provide a full complement of micro-scale treatment options that can effectively manage IOP and overcome many of the drawbacks of conventional therapies,” said Thomas Burns, Glaukos president and chief executive officer. “Peer-reviewed study results like these help to illustrate the potential for our technologies to offer important clinical and economic benefits for physicians, patients and the healthcare system.”
The full Journal of Medical Economics article is available here.